-
公开(公告)号:EP3822262B1
公开(公告)日:2024-03-27
申请号:EP20213929.1
申请日:2016-08-03
-
公开(公告)号:EP4219464A1
公开(公告)日:2023-08-02
申请号:EP23151669.1
申请日:2019-03-25
申请人: Pfizer Inc.
发明人: ZHANG, Lei , LACHAPELLE, Erik Alphie , BUTLER, Christopher, Ryan , KABLAOUI, Natasha Mariam , BRODNEY, Michael Aaron , MCALLISTER, Laura Ann , YANG, Qingyi , HELAL, Christopher, John , WEBB, Damien
IPC分类号: C07D401/14 , C07D413/14 , C07D401/08 , C07D417/14 , C07D471/04 , C07D491/107 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61P31/00 , A61P11/00 , A61P25/16 , A61P13/00 , A61P25/28 , A61P25/18 , A61P25/30 , A61P11/06 , A61P25/10
摘要: The present invention provides, in part, compounds of Formula I:
or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X 1 , X 2 , R 1 , R 2 , m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N -oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.-
公开(公告)号:EP3526207B1
公开(公告)日:2021-09-08
申请号:EP17787581.2
申请日:2017-10-16
IPC分类号: C07D401/08 , C07D403/08 , C07D243/08 , C07D471/04 , C07D471/10 , C07D487/10 , C07D207/42 , A61K31/551 , A61K31/401 , A61K31/437 , A61K31/4439 , A61K31/438 , A61K31/4353 , A61P25/00 , C07D413/12
-
公开(公告)号:EP3029033B1
公开(公告)日:2021-06-16
申请号:EP14831835.5
申请日:2014-07-29
IPC分类号: C07D401/08 , C07D409/14 , C07D413/08 , C07D417/08 , C09K11/06 , H01L51/54
-
公开(公告)号:EP3571191A1
公开(公告)日:2019-11-27
申请号:EP18703621.5
申请日:2018-01-08
申请人: Pfizer Inc.
发明人: BRODNEY, Michael Aaron , BUTLER, Christopher Ryan , MCALLISTER, Laura Ann , HELAL, Christopher John , O'NEIL, Steven Victor , VERHOEST, Patrick Robert
IPC分类号: C07D401/08 , C07D401/12 , C07D491/10 , C07D295/185 , A61K31/4747 , A61P35/00
-
公开(公告)号:EP3562822A1
公开(公告)日:2019-11-06
申请号:EP17832694.8
申请日:2017-12-28
申请人: Mitobridge, Inc.
发明人: TAKAHASHI, Taisuke , KLUGE, Arthur , LAGU, Bharat , JI, Nan
IPC分类号: C07D401/14 , C07D401/08 , C07D403/08 , C07D405/10 , C07D239/74 , C07D417/08 , C07D487/04 , A61K31/517 , A61P35/00
-
公开(公告)号:EP3080087B1
公开(公告)日:2019-05-22
申请号:EP14870064.4
申请日:2014-12-10
申请人: Lycera Corporation
IPC分类号: C07D231/38 , A61K31/155 , C07D401/08 , C07D403/04 , C07D405/08 , C07D405/04 , C07D401/04
-
公开(公告)号:EP3366674A1
公开(公告)日:2018-08-29
申请号:EP16857419.2
申请日:2016-10-18
IPC分类号: C07D213/65 , A01N43/40 , A01N43/50 , A01N43/54 , A01N43/56 , A01N43/60 , A01N43/647 , A01N43/653 , A01N43/824 , A01N43/836 , A01N47/20 , A01N53/12 , A01P7/04 , C07D213/89 , C07D401/08 , C07D413/08 , C07D417/08
CPC分类号: C07D213/65 , A01N43/40 , A01N43/50 , A01N43/54 , A01N43/56 , A01N43/60 , A01N43/647 , A01N43/653 , A01N43/82 , A01N47/20 , C07D213/89 , C07D401/08 , C07D401/10 , C07D413/08 , C07D413/10 , C07D417/08 , C07D417/10
摘要: A pyridine compound represented by formula (1)
[wherein: R 1 represents a C2-C10 haloalkyl group or the like; R 2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like; R 3 represents a C1-C6 chain hydrocarbon group or the like; R 6 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like; n represents 0, 1, or 2; p and q represent each independently 0, 1, 2, or 3] or an N-oxide thereof has excellent control efficacies against harmful arthropods.-
9.
公开(公告)号:EP3292104A1
公开(公告)日:2018-03-14
申请号:EP16720441.1
申请日:2016-05-04
申请人: Astrazeneca AB
发明人: RONN, Robert , LINDH, Carl, Jonas , RINGBERG, Erik , ANDERSSON, Hanna, Birgitta, Ellinor , NILSSON, Peter , SCHAAL, Wesley, Ralph , MUNCK AF ROSENSCHÖLD, Magnus , NIKITIDIS, Antonios , NIKITIDIS, Grigorios , JOHANNESSON, Petra , TYRCHAN, Christian
IPC分类号: C07D213/74 , C07D401/08 , C07D239/42 , C07D241/20 , A61K31/44 , A61K31/4439 , A61K31/496 , A61K31/505 , A61P11/00 , A61P29/00
CPC分类号: A61K31/4965 , A61K31/44 , A61K31/4439 , A61K31/496 , A61K31/505 , C07C211/55 , C07C211/58 , C07D213/74 , C07D215/38 , C07D239/42 , C07D239/47 , C07D241/20 , C07D401/08 , C07D401/12 , C07D405/12
摘要: wherein E1, E2, E3, E4, L1, Y1, Y2, Y3, Ra and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.
-
公开(公告)号:EP3030554B1
公开(公告)日:2018-02-28
申请号:EP14738740.1
申请日:2014-07-09
申请人: Merck Patent GmbH
IPC分类号: C07D401/14 , C07D401/06 , C07D401/08 , C07D401/12 , C07D211/32 , A61K31/4545 , A61P35/00 , A61P37/00 , A61P25/28 , A61P9/00
CPC分类号: A61K31/445 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/501 , C07D211/32 , C07D401/06 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14
摘要: Compounds of the formula I in which R1-R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
-
-
-
-
-
-
-
-
-